Raxtozinameran
Highest phase reached
Phase 2
Drug type
Oligonucleotide
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Oligonucleotide
- Drug name
- Raxtozinameran
- BNT162B2 OMICRON (XBB.1.5)
- bnt162b2 omicron xbb 1 5
- messenger RNA (mRNA), 5'-capped, encoding a full-length, codon-optimised pre-fusion stabilised conformation variant (K982P and V983P) of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) spike (S) glycoprotein (Omicron sub-lineage XBB.1.5; based upon GISAID:EPI_ISL_17157779), flanked by 5' and 3' untranslated regions and a 3' polyadenylation (polyA) tail; contains N<sup>1</sup>-methylpseudouridine instead of uridine (all-U>m<sup>1</sup>Ψ)
- messenger rna mrna 5 capped encoding a full length codon optimised pre fusion stabilised conformation variant k982p and v983p of the sars cov 2 severe acute respiratory syndrome coronavirus 2 spike s glycoprotein omicron sub lineage xbb 1 5 based upon gisaid epi isl 17157779 flanked by 5 and 3 untranslated regions and a 3 polyadenylation polya tail contains n sup 1 sup methylpseudouridine instead of uridine all u m sup 1 sup ψ
- raxtozinameran
- Raxtozinameran
- raxtozinameran [INN]
- Raxtozinameran [WHO-DD]
- raxtozinameran inn
- raxtozinameran who dd
- rbp 020 2 4 xbb 1 5 variant
- Rbp-020.2 4 (xbb.1.5 variant)
- RNA (recombinant 5′-[1,2-[(3′-O-methyl)m7G-(5′→5′)-ppp-Am]]-capped all uridine→N1-methylpseudouridine-substituted severe acute respiratory syndrome coronavirus 2 spike glycoprotein secretory signal peptide plus codon-optimized pre-fusion spike glycoprotein omicron XBB.1.5 variant [982-proline,983-proline]-specifying plus 5′-and 3′-untranslated flanking region-containing poly(A)-tailed messengerRBP020.2 4), inner salt
- rna recombinant 5 1 2 3 o methyl m7g 5 5 ppp am capped all uridine n1 methylpseudouridine substituted severe acute respiratory syndrome coronavirus 2 spike glycoprotein secretory signal peptide plus codon optimized pre fusion spike glycoprotein omicron xbb 1 5 variant 982 proline 983 proline specifying plus 5 and 3 untranslated flanking region containing poly a tailed messengerrbp020 2 4 inner salt
- CAS registry numbers
- 2887554-49-4
- ChEMBL ID
- CHEMBL5314803
- FDA ingredient codes (UNII)
- N36VHK46PR
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -meran
Investigated indications
- Condition
- COVID-19
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D000086382
Open Targets indications
- Condition identifier
- MONDO_0100096
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (2)
- A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
- Korea Comirnaty Post-marketing Surveillance
In development for (1)
- COVID-19 Phase 2